Colorectal Neoplasm Clinical Trials in Madrid

9 recruitingMadrid, Spain

Showing 19 of 9 trials

Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 1

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

Colorectal Neoplasms
Janssen Research & Development, LLC380 enrolled9 locationsNCT07107230
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled381 locationsNCT05253651
Recruiting
Phase 1

First in Human Study of AZD9592 in Solid Tumors

Carcinoma, Non-Small Cell LungColorectal NeoplasmsHead and Neck Neoplasms+1 more
AstraZeneca403 enrolled51 locationsNCT05647122
Recruiting
Phase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Colorectal NeoplasmsGastrointestinal Neoplasms
Janssen Research & Development, LLC220 enrolled11 locationsNCT06663319
Recruiting
Phase 1

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Carcinoma, Non-Small Cell LungGastroesophageal Junction AdenocarcinomaStomach Neoplasms+3 more
Seagen, a wholly owned subsidiary of Pfizer914 enrolled44 locationsNCT06131840
Recruiting

Early Onset Colorectal Cancer Detection

Colorectal, CancerColorectal NeoplasmsColorectal Adenocarcinoma+5 more
City of Hope Medical Center400 enrolled13 locationsNCT06342401
Recruiting
Phase 1

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Carcinoma, Non-Small Cell LungOvarian NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company495 enrolled23 locationsNCT06400472